Last10K.com

Respirerx Pharmaceuticals Inc. (RSPI) SEC Filing 10-Q Quarterly report for the period ending Tuesday, June 30, 2020

SEC Filings

RSPI Valuations

Intrinsic Value
Financial Stability
Financial Ratios
Insider Trades
Manager Portfolios
Notifications

RSPI Annual Reports

RSPI Quarterly Reports

RSPI Corporate News

RSPI Registration of Securities

Respirerx Pharmaceuticals Inc.

HISTORY TOOLS
CIK: 849636 Ticker: RSPI
Document and Entity Information - shares
6 Months Ended
Jun. 30, 2020
Aug. 17, 2020
Cover [Abstract]  
Entity Registrant NameRespireRx Pharmaceuticals Inc. 
Entity Central Index Key0000849636 
Document Type10-Q 
Document Period End DateJun. 30, 2020 
Amendment Flagfalse 
Current Fiscal Year End Date--12-31 
Entity Reporting Status CurrentYes 
Entity Interactive Data CurrentYes 
Entity Filer CategoryNon-accelerated Filer 
Entity Small Business Flagtrue 
Entity Emerging Growth Companyfalse 
Entity Shell Companyfalse 
Entity Common Stock, Shares Outstanding 307,430,693
Document Fiscal Period FocusQ2 
Document Fiscal Year Focus2020 

View differences made from one quarter to another to evaluate Respirerx Pharmaceuticals Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Respirerx Pharmaceuticals Inc..

Continue

Assess how Respirerx Pharmaceuticals Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Respirerx Pharmaceuticals Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2020 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Document And Entity Information
Condensed Consolidated Balance Sheets
Condensed Consolidated Balance Sheets (Parenthetical)
Condensed Consolidated Statements Of Cash Flows (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited)
Condensed Consolidated Statements Of Operations (Unaudited) (Parenthetical)
Condensed Consolidated Statements Of Stockholders' Deficiency (Unaudited)
Business
Business (Details Narrative)
Commitments And Contingencies
Commitments And Contingencies (Details Narrative)
Commitments And Contingencies (Tables)
Commitments And Contingencies - Summary Of Principal Cash Obligations And Commitments (Details)
Notes Payable
Notes Payable (Details Narrative)
Notes Payable (Tables)
Notes Payable - Schedule Of Convertible Notes Payable (Details)
Notes Payable - Summary Of Note Payable To Related Party (Details)
Organization And Basis Of Presentation
Related Party Transactions
Settlement And Payment Agreements
Settlement And Payment Agreements (Details Narrative)
Stockholders' Deficiency
Stockholders' Deficiency (Details Narrative)
Stockholders' Deficiency (Tables)
Stockholders' Deficiency - Schedule Of Exercise Prices Of Common Stock Options Outstanding And Exercisable (Details)
Stockholders' Deficiency - Schedule Of Exercise Prices Of Common Stock Warrants Outstanding And Exercisable (Details)
Stockholders' Deficiency - Schedule Of Warrants Activity (Details)
Stockholders' Deficiency - Summary Of Stock Option Activity (Details)
Subsequent Events
Subsequent Events (Details Narrative)
Subsequent Events (Tables)
Subsequent Events - Summary Of Conversions Of Convertible Notes (Details)
Subsequent Events - Summary Of Exercises Of Warrants (Details)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies (Tables)
Summary Of Significant Accounting Policies - Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share (Details)

Material Contracts, Statements, Certifications & more

Respirerx Pharmaceuticals Inc. provided additional information to their SEC Filing as exhibits

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Exhibit 32.2: Section 1350 Certification
Ticker: RSPI
CIK: 849636
Form Type: 10-Q Quarterly Report
Accession Number: 0001493152-20-016297
Submitted to the SEC: Wed Aug 19 2020 3:41:12 PM EST
Accepted by the SEC: Wed Aug 19 2020
Period: Tuesday, June 30, 2020
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media

Bookmark the Permalink:
https://last10k.com/sec-filings/rspi/0001493152-20-016297.htm